Nihan TEKKARIŞMAZ, Ahmet Eftal YÜCEL, Müge AYDIN TUFAN

Factors affecting relapse in patients with Granulomatosis Polyangiitis: a single-center retrospective cohort study

Background and aim: This study aimed to determine the frequency of relapse, the risk factors for relapse, and the correlation of relapse with immunosuppressive regimens in patients with granulomatosis polyangiitis (GPA). Materials and methods: The demographic characteristics, the clinical, laboratory, and radiological findings, the immunosuppressive treatment regimens, and the remission and relapse rates of 50 patients with GPA were obtained retrospectively from medical records. Results: The mean relapse-free survival rates at years 1, 3, and 5 were 82%, 60%, and 50%, respectively. Increased relapse rates were observed in patients who had cavitary lung lesions (52.2% vs. 22.2%, p = 0.04) and in those who had elevated serum creatinine levels (1.8 vs. 0.9, p = 0.00). The patients received two different types of remission induction therapies; 36% of them received the combination therapy involving cyclophosphamide (CYC) and rituximab (RTX), and 62% received CYC alone. Relapse was observed in 22.3% of the patients who received the combination remission induction therapy and in 61.3% of the patients who received CYC alone (P = 0.003). Conclusion: An increased risk of relapse was observed in patients who had cavitary lung lesions and in those who had elevated serum creatinine levels. The combined use of RTX and CYC for the remission therapy in GPA reduced the relapse rates compared with the use of CYC alone.Key words: Granulomatous polyangiitis, relapse, vasculitis

PDF

___

1. Comarmond C, Cacoub P. Granulomatosis with polyangiitis (Wegener): clinical aspects and treatment. Autoimmunity Reviews 2014; 13 (11): 1121-1125. doi: 10.1016/j. autrev.2014.08.017
2. King C, Harper L, Little M. The complications of vasculitis and its treatment. Best Practice & Research: Clinical Rheumatology 2018; 32 (1): 125-136. doi: 10.1016/j.berh.2018.07.009
3. Mukhtyar C, Flossmann O, Hellmich B, Bacon P, Cid M et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European league against rheumatism systemic vasculitis task force. Annals of the Rheumatic Diseases 2008; 67 (7): 1004-1010. doi: 10.1136/ard.2007.071936
4. Pagnoux C, Hogan SL, Chin H, Jennette JC, Falk RJ et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. Arthritis & Rheumatism 2008; 58 (9): 2908-2918. doi: 10.1002/art.23800
5. Emejuaiwe N. Treatment strategies in ANCA-associated vasculitis. Current Rheumatology Reports 2019; 21 (7): 33. doi: 10.1007/s11926-019-0835-8
6. Solans-Laqué R, Fraile G, Rodriguez-Carballeira M, Caminal L, Castillo MJ et al. Clinical characteristics and outcome of Spanish patients with ANCA-associated vasculitides: impact of the vasculitis type, ANCA specificity, and treatment on mortality and morbidity. Medicine (Baltimore) 2017; 96 (8): e6083. doi: 10.1097/MD.0000000000006083
7. Outh R, Lemaire A, Mania A, Berland P, Gerbaud L et al. Relapses in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis: a retrospective study. Clinical Rheumatology 2020; 39 (5): 1601-1608. doi: 10.1007/s10067- 019-04816-7
8. Hogan SL, Falk RJ, Chin H, Cai J, Jennette CE et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Annals of Internal Medicine 2005; 143 (9) : 621-31. doi: 10.7326/0003-4819-143- 9-200511010-00005
9. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS et al. Wegener granulomatosis: an analysis of 158 patients. Annals of Internal Medicine 1992; 116 (6): 488-498. doi: 10.7326/0003- 4819-116-6-488
10. Salmela A, Törnroth T, Poussa T, Ekstrand A. Prognostic factors for survival and relapse in ANCA-associated vasculitis with renal involvement: a clinical long-term follow-up study. International Journal of Nephrology 2018; 16; 2018: 6369814. doi: 10.1155/2018/6369814
11. Lhote R, Chilles M, Groh M, Puéchal X, Guilpain P et al.. Spectrum and prognosis of antineutrophil cytoplasmic antibody-associated vasculitis-related bronchiectasis: data from 61 patients. The Journal of Rheumatology 2020; 47 (10): 1522-1531. doi: 10.3899/jrheum.190313
12. Russell B, Mohan S, Chahal R, Carette S, Pagnoux C. Prognostic significance of cavitary lung nodules in granulomatosis with polyangiitis (Wegener’s): a clinical imaging study of 225 patients. Arthritis Care & Research (Hoboken) 2018; 70 (7): 1082-1089. doi: 10.1002/acr.23443
13. Komócsi A, Reuter M, Heller M, Muraközi H, Gross WL et al. Active disease and residual damage in treated Wegener’s granulomatosis: an observational study using pulmonary highresolution computed tomography. European Radiology 2003; 13 (1): 36-42. doi: 10.1007/s00330-002-1403-5
14. Chen M, Yu F, Zhao MH. Relapses in patients with antineutrophil cytoplasmic autoantibody-associated vasculitis: likely to begin with the same organ as initial onset. The Journal of Rheumatology 2008; 35 (3): 448-450.
15. Walsh M, Flossmann O, Berden A, Westman K, Höglund P et al. Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis & Rheumatology 2012; 64 (2): 542-548. doi: 10.1002/art.33361
16. Li ZY, Chang DY, Zhao MH, Chen M. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibodyassociated vasculitis: a study of 439 cases in a single Chinese center. Arthritis & Rheumatology 2014; 66 (7): 1920-1926. doi: 10.1002/art.38621
17. Rhee RL, Davis JC, Ding L, Fervenza FC, Hoffman GS et al. The utility of urinalysis in determining the risk of renal relapse in ANCA-associated casculitis. Clinical Journal of the American Society of Nephrology 2018; 13 (2): 251-257. doi: 10.2215/ CJN.04160417
18. Lega JC, Seror R, Fassier T, Aumaître O, Quere I et al. Characteristics, prognosis, and outcomes of cutaneous ischemia and gangrene in systemic necrotizing vasculitides: a retrospective multicenter study. Seminars in Arthritis and Rheumatism 2014; 43 (5): 681-688. doi: 10.1016/j. semarthrit.2013.09.001
19. Tomasson G, Grayson PC, Mahr AD, Lavalley M, Merkel PA. Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis — a meta-analysis. Rheumatology (Oxford) 2012; 51 (1): 100-109. doi: 10.1093/ rheumatology/ker280
20. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA et al.. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. The New England Journal of Medicine 2010; 363 (3): 221-232. doi: 10.1056/NEJMoa0909905
21. Biedroń G, Włudarczyk A, Wawrzycka-Adamczyk K, Wójcik K, Sznajd J et al. Treatment and its side effects in ANCAassociated vasculitides - study based on POLVAS registry data. Advances in Medical Sciences 2020; 65 (1): 156-162. doi: 10.1016/j.advms.2020.01.002
22. Jones RB, Furuta S, Tervaert JW, Hauser T, Luqmani R et al.. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Annals of the Rheumatic Diseases 2015; 74 (6):1178-1182. doi: 10.1136/ annrheumdis-2014-206404.
23. Besada E, Koldingsnes W, Nossent JC. Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centre. Rheumatology (Oxford) 2013; 52 (11): 2041-2017. doi: 10.1093/rheumatology/ket257
24. Cortazar FB, Muhsin SA, Pendergraft WF, Wallace ZS, Dunbar C et al. Combination therapy with rituximab and cyclophosphamide for remission induction in ANCA Vasculitis. Kidney International Reports 2017; 3 (2): 394-402. doi: 10.1016/j.ekir.2017.11.004
25. Pepper RJ, McAdoo SP, Moran SM, Kelly D, Scott J et al. A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford) 2019; 58 (2): 260-268. doi: 10.1093/rheumatology/ key288
26. De Joode AAE, Sanders JSF, Puéchal X, Guillevin LP, Hiemstra TF et al. Long term azathioprine maintenance therapy in ANCA-associated vasculitis: combined results of long-term follow-up data. Rheumatology (Oxford) 2017; 56 (11): 1894- 1901. doi:10.1093/rheumatology/kex281
27. Puéchal X, Pagnoux C, Perrodeau É, Hamidou M, Boffa JJ et al. French vasculitis study group. Long-term outcomes among participants in the WEGENT trial of remission-maintenance therapy for granulomatosis with polyangiitis (Wegener’s) or microscopic polyangiitis. Arthritis & Rheumatology 2016; 68 (3): 690-701. doi: 10.1002/art.39450
28. Terrier B, Pagnoux C, Perrodeau É, Karras A, Khouatra C et al. French vasculitis study group. Long-term efficacy of remissionmaintenance regimens for ANCA-associated vasculitides. Annals of the Rheumatic Diseases 2018; 77 (8): 1150-1156. doi:10.1136/annrheumdis-2017-212768